November 2, 2005
Cougar Biotechnology Announces Presentation at Rodman & Renshaw
Techvest 7th Annual Healthcare Conference
Los Angeles, CA, November 2, 2005 - Cougar Biotechnology, Inc, a privately held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Wednesday, November 9th at 8:20 AM EST at the New York Palace Hotel in New York, NY. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.
A live webcast of the presentation can be accessed on the Company's website at www.cougarbiotechnology.com. The presentation will also be archived shortly after the live event and available online for 90 days following the conference.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar&39;s oncology portfolio includes CB7630, which has completed Phase I clinical trials in prostate cancer, CB3304, which is currently being tested in a Phase I trial in non-Hodgkin's lymphoma and CB1089, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach, Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
Notes:
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust work in partnership to form Europe's largest comprehensive cancer centre.
|
Dedicated to Innovative Treatments...
|
|
